Do LGI1, AQP4, and GM1 autoantibodies disrupt nervous-system function?

Autoantibodies against LGI1, aquaporin-4 (AQP4), and GM1 have distinct neural targets, but each has strong evidence for biologically meaningful disruption of nervous-system function.

Clinical and mechanistic evidence

• LGI1 antibodies: Patient-derived IgG disrupts LGI1 binding to ADAM22/ADAM23, reduces hippocampal Kv1.1 and AMPA-receptor abundance, increases excitability, and impairs CA1 long-term potentiation. In infused mice, these changes accompanied reversible novel-object-recognition deficits. This provides direct support for an antibody-mediated contribution to memory-relevant hippocampal dysfunction in anti-LGI1 encephalitis, although clinical memory impairment also reflects seizures, inflammation, structural injury, and treatment timing.

• AQP4 antibodies: AQP4-IgG directly targets AQP4 concentrated at perivascular astrocyte endfeet, defining astrocytes as the central cellular target in AQP4-IgG-positive NMOSD. Its IgG1 Fc domain recruits C1q and activates the classical complement cascade, producing inflammatory injury and membrane-attack-complex-mediated astrocyte damage. Human lesions show AQP4 and GFAP loss with perivascular immunoglobulin and activated-complement deposition. Antibody binding may also promote AQP4 clustering/internalization and astrocyte-endfoot dysfunction before cell destruction.

• GM1 antibodies: Anti-GM1 antibodies are most closely linked to AMAN and multifocal motor neuropathy. In a systematic review of 36 MMN studies, IgM anti-GM1 ELISA sensitivity was 45.6% and specificity 88.8%, so a positive result is supportive rather than diagnostic. Mechanistically, antibody and complement deposition at motor-nerve nodes disrupt sodium-channel clusters, nodal/paranodal architecture, and conduction; severe injury can progress to axonal degeneration.

Bottom line

• The claim is strongly supported: LGI1 antibodies can impair memory-related synaptic function, AQP4-IgG targets and injures astrocytes—often via complement—and GM1 antibodies are associated with complement-mediated peripheral motor-nerve nodal injury. Individual antibody results require phenotype-specific clinical and electrophysiologic interpretation.